Digitala Vetenskapliga Arkivet

Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies
Case Western Reserve Univ, OH USA; Univ Hosp Cleveland Med Ctr, OH USA.
Linköping University, Department of Health, Medicine and Caring Sciences, Division of Diagnostics and Specialist Medicine. Linköping University, Faculty of Medicine and Health Sciences. AMRA Med AB, Linkoping, Sweden.ORCID iD: 0000-0001-7399-8375
Eberhard Karls Univ Tubingen, Germany; German Ctr Diabet Res DZD, Germany; Eberhard Karls Univ Tubingen, Germany; Kings Coll London, England.
2024 (English)In: Diabetes, obesity and metabolism, ISSN 1462-8902, E-ISSN 1463-1326, Vol. 26, no Suppl 4, p. 16-27Article in journal (Refereed) Published
Abstract [en]

Weight loss induced by glucagon-like peptide-1 receptor agonists (GLP-1RAs) and dual glucagon-like peptide-1 receptor (GLP-1R)/glucose-dependent insulinotropic polypeptide receptor agonists is coming closer to the magnitudes achieved with surgery. However, with greater weight loss there is concern about potential side effects on muscle quantity (mass), health and function. There is heterogeneity in the reported effects of GLP-1-based therapies on lean mass changes in clinical trials: in some studies, reductions in lean mass range between 40% and 60% as a proportion of total weight lost, while other studies show lean mass reductions of approximately 15% or less of total weight lost. There are several potential reasons underlying this heterogeneity, including population, drug-specific/molecular, and comorbidity effects. Furthermore, changes in lean mass may not always reflect changes in muscle mass as the former measure includes not only muscle but also organs, bone, fluids, and water in fat tissue. Based on contemporary evidence with the addition of magnetic resonance imaging-based studies, skeletal muscle changes with GLP-1RA treatments appear to be adaptive: reductions in muscle volume seem to be commensurate with what is expected given ageing, disease status, and weight loss achieved, and the improvement in insulin sensitivity and muscle fat infiltration likely contributes to an adaptive process with improved muscle quality, lowering the probability for loss in strength and function. Nevertheless, factors such as older age and severity of disease may influence the selection of appropriate candidates for these therapies due to risk of sarcopenia. To further improve muscle health during weight loss, several pharmacological treatments to maintain or improve muscle mass designed in combination with GLP-1-based therapies are under development. Future research on GLP-1-based and other therapies designed for weight loss should focus on more accurate and meaningful assessments of muscle mass, composition, as well as function, mobility or strength, to better define their impact on muscle health for the substantial number of patients who will likely be taking these medications well into the future.

Place, publisher, year, edition, pages
WILEY , 2024. Vol. 26, no Suppl 4, p. 16-27
Keywords [en]
cardiovascular disease; GLP-1 receptor agonist; insulin resistance; muscle; obesity; sarcopenia; type 2 diabetes
National Category
Physiology and Anatomy
Identifiers
URN: urn:nbn:se:liu:diva-206612DOI: 10.1111/dom.15728ISI: 001257916900001PubMedID: 38937282OAI: oai:DiVA.org:liu-206612DiVA, id: diva2:1890977
Note

Funding Agencies|Nestle

Available from: 2024-08-21 Created: 2024-08-21 Last updated: 2025-04-15Bibliographically approved

Open Access in DiVA

fulltext(1952 kB)1448 downloads
File information
File name FULLTEXT01.pdfFile size 1952 kBChecksum SHA-512
b6faa1f6c2805378e447d4fdf6b3716d267b83dd2a2f9532987b4e2fb7db042e998f7076a605299df348d25d10faa5ef55700245459c3eafdf2bcedf5989f8cc
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Linge, Jennifer
By organisation
Division of Diagnostics and Specialist MedicineFaculty of Medicine and Health Sciences
In the same journal
Diabetes, obesity and metabolism
Physiology and Anatomy

Search outside of DiVA

GoogleGoogle Scholar
Total: 1449 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 424 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf